Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial

BACKGROUND: Ovarian clear cell carcinoma (OCCC) has an abysmal prognosis with a median overall survival (OS) of 25.3 months because of a low response to chemotherapy. The 5-year disease-specific survival rate after recurrence is 13.2%, with more than two-thirds of the patients dying within a year. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ruyuan, Liu, Xingyu, Song, Chunyan, Zhang, Wei, Liu, Jiahao, Jiao, Xiaofei, Yu, Yang, Zeng, Shaoqing, Chi, Jianhua, Zhao, Yingjun, Ma, Guanchen, Huo, Yabing, Li, Ming, Peng, Zikun, Li, Guiling, Jiang, Jie, Gao, Qing-Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131073/
https://www.ncbi.nlm.nih.gov/pubmed/35613822
http://dx.doi.org/10.1136/bmjopen-2021-058132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131073/
https://www.ncbi.nlm.nih.gov/pubmed/35613822
http://dx.doi.org/10.1136/bmjopen-2021-058132

Ejemplares similares